ES2625316T3 - Neuquinasa, una proteína corriente abajo de neuregulina - Google Patents
Neuquinasa, una proteína corriente abajo de neuregulina Download PDFInfo
- Publication number
- ES2625316T3 ES2625316T3 ES13184566.1T ES13184566T ES2625316T3 ES 2625316 T3 ES2625316 T3 ES 2625316T3 ES 13184566 T ES13184566 T ES 13184566T ES 2625316 T3 ES2625316 T3 ES 2625316T3
- Authority
- ES
- Spain
- Prior art keywords
- neukinase
- dna
- activity
- seq
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 title description 51
- 102000004169 proteins and genes Human genes 0.000 title description 14
- 102000014413 Neuregulin Human genes 0.000 title 1
- 108050003475 Neuregulin Proteins 0.000 title 1
- 238000000034 method Methods 0.000 abstract description 41
- 230000000694 effects Effects 0.000 abstract description 39
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 26
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 24
- 239000003795 chemical substances by application Substances 0.000 abstract description 23
- 229920001184 polypeptide Polymers 0.000 abstract description 23
- 230000004071 biological effect Effects 0.000 abstract description 13
- 238000006366 phosphorylation reaction Methods 0.000 abstract description 12
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 11
- 238000000338 in vitro Methods 0.000 abstract description 11
- 230000026731 phosphorylation Effects 0.000 abstract description 11
- 238000012216 screening Methods 0.000 abstract description 6
- 102000013602 Cardiac Myosins Human genes 0.000 abstract description 2
- 108010051609 Cardiac Myosins Proteins 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 51
- 210000004027 cell Anatomy 0.000 description 42
- 239000002299 complementary DNA Substances 0.000 description 31
- 239000012634 fragment Substances 0.000 description 30
- 150000007523 nucleic acids Chemical class 0.000 description 26
- 108020004999 messenger RNA Proteins 0.000 description 25
- 108020004707 nucleic acids Proteins 0.000 description 23
- 102000039446 nucleic acids Human genes 0.000 description 23
- 241000282414 Homo sapiens Species 0.000 description 21
- 108091000080 Phosphotransferase Proteins 0.000 description 21
- 102000020233 phosphotransferase Human genes 0.000 description 21
- 108091030071 RNAI Proteins 0.000 description 20
- 230000009368 gene silencing by RNA Effects 0.000 description 20
- 239000013615 primer Substances 0.000 description 20
- 238000003752 polymerase chain reaction Methods 0.000 description 18
- 239000000523 sample Substances 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 238000006467 substitution reaction Methods 0.000 description 11
- 102000000584 Calmodulin Human genes 0.000 description 10
- 108010041952 Calmodulin Proteins 0.000 description 10
- 102000001253 Protein Kinase Human genes 0.000 description 10
- 238000010367 cloning Methods 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 108060006633 protein kinase Proteins 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 239000000556 agonist Substances 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 108700019146 Transgenes Proteins 0.000 description 6
- 230000001594 aberrant effect Effects 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 6
- 239000013599 cloning vector Substances 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 102000018120 Recombinases Human genes 0.000 description 4
- 108010091086 Recombinases Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 210000003000 inclusion body Anatomy 0.000 description 4
- 230000002452 interceptive effect Effects 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000016349 Myosin Light Chains Human genes 0.000 description 3
- 108010067385 Myosin Light Chains Proteins 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
- 210000005003 heart tissue Anatomy 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000002853 nucleic acid probe Substances 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000007423 screening assay Methods 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- 102100035044 Myosin light chain kinase, smooth muscle Human genes 0.000 description 2
- 108010074596 Myosin-Light-Chain Kinase Proteins 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- -1 Val Chemical compound 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000001215 fluorescent labelling Methods 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 210000002729 polyribosome Anatomy 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 1
- PMGDADKJMCOXHX-BQBZGAKWSA-N Arg-Gln Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O PMGDADKJMCOXHX-BQBZGAKWSA-N 0.000 description 1
- NPDLYUOYAGBHFB-WDSKDSINSA-N Asn-Arg Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NPDLYUOYAGBHFB-WDSKDSINSA-N 0.000 description 1
- RJUHZPRQRQLCFL-IMJSIDKUSA-N Asn-Asn Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(O)=O RJUHZPRQRQLCFL-IMJSIDKUSA-N 0.000 description 1
- QJMCHPGWFZZRID-BQBZGAKWSA-N Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(N)=O QJMCHPGWFZZRID-BQBZGAKWSA-N 0.000 description 1
- FRYULLIZUDQONW-IMJSIDKUSA-N Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FRYULLIZUDQONW-IMJSIDKUSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000702191 Escherichia virus P1 Species 0.000 description 1
- 108010046276 FLP recombinase Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 230000035519 G0 Phase Effects 0.000 description 1
- KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- JWBLQDDHSDGEGR-DRZSPHRISA-N Phe-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 JWBLQDDHSDGEGR-DRZSPHRISA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- XPFVYQJUAUNWIW-UHFFFAOYSA-N furfuryl alcohol Chemical compound OCC1=CC=CO1 XPFVYQJUAUNWIW-UHFFFAOYSA-N 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 108010009355 microbial metalloproteinases Proteins 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229920000368 omega-hydroxypoly(furan-2,5-diylmethylene) polymer Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 238000003566 phosphorylation assay Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83938806P | 2006-08-21 | 2006-08-21 | |
| US839388P | 2006-08-21 | ||
| US92165507P | 2007-04-02 | 2007-04-02 | |
| US921655P | 2007-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2625316T3 true ES2625316T3 (es) | 2017-07-19 |
Family
ID=39156831
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13184566.1T Active ES2625316T3 (es) | 2006-08-21 | 2007-08-21 | Neuquinasa, una proteína corriente abajo de neuregulina |
| ES12154752.5T Active ES2555543T3 (es) | 2006-08-21 | 2007-08-21 | Neuquinasa, una proteína secuencia abajo de la neuregulina |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12154752.5T Active ES2555543T3 (es) | 2006-08-21 | 2007-08-21 | Neuquinasa, una proteína secuencia abajo de la neuregulina |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9580515B2 (enExample) |
| EP (4) | EP2059594B1 (enExample) |
| JP (4) | JP2010501167A (enExample) |
| CN (2) | CN101553568B (enExample) |
| CA (1) | CA2661308C (enExample) |
| ES (2) | ES2625316T3 (enExample) |
| WO (1) | WO2008028405A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3211592B2 (ja) | 1994-11-21 | 2001-09-25 | トヨタ自動車株式会社 | 樹脂製品の製造方法 |
| AUPP785098A0 (en) | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
| AU2002304965A1 (en) * | 2002-05-24 | 2003-12-12 | Zensun (Shanghai) Sci-Tech.Ltd | Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy |
| ES2664086T3 (es) | 2005-12-30 | 2018-04-18 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Liberación extendida de neurregulina para mejorar la función cardíaca |
| US20090156488A1 (en) * | 2007-09-12 | 2009-06-18 | Zensun (Shanghai) Science & Technology Limited | Use of neuregulin for organ preservation |
| JP2009242388A (ja) * | 2008-03-14 | 2009-10-22 | National Cardiovascular Center | 心臓特異的キナーゼの心不全診断および治療への応用 |
| CN102232084B (zh) * | 2008-11-28 | 2014-05-28 | 上海泽生科技开发有限公司 | 纽兰格林及其用途 |
| CN102231987A (zh) * | 2008-11-28 | 2011-11-02 | 上海泽生科技开发有限公司 | 纽兰格林和心脏干细胞 |
| JP6096262B2 (ja) | 2009-08-25 | 2017-03-15 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． | ニューレグリンに基づく心不全の治療方法 |
| CN102139095A (zh) | 2010-01-29 | 2011-08-03 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物 |
| WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| EP2903632A4 (en) | 2012-10-08 | 2016-07-13 | Zensun Shanghai Science And Technology Ltd | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE IN DIABETES PATIENTS |
| ES2743617T3 (es) | 2013-05-22 | 2020-02-20 | Zensun Shanghai Science & Tech Co Ltd | Liberación prolongada de neuregulina para tratar la insuficiencia cardíaca |
| CN110946993A (zh) | 2014-01-03 | 2020-04-03 | 上海泽生科技开发股份有限公司 | 纽兰格林制剂的配方 |
| CN105497876B (zh) | 2014-09-24 | 2021-01-15 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物 |
| CN111407882A (zh) | 2014-10-17 | 2020-07-14 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
| CN106177992A (zh) * | 2015-05-08 | 2016-12-07 | 上海泽生科技开发有限公司 | cMLCK基因导入 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873191A (en) * | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4870009A (en) * | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
| US5272065A (en) * | 1983-10-20 | 1993-12-21 | Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
| US4736866A (en) * | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
| US4980286A (en) * | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5906810A (en) * | 1987-03-17 | 1999-05-25 | Turner; Robert E. | Formulations and uses thereof in the prevention and treatment of oral lesions |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| DE69034263D1 (de) | 1989-07-25 | 2009-04-02 | Cell Genesys Inc | Homologe Rekombination für universelle Donorzellen und chimerische Säugetierzellen |
| JP3127158B2 (ja) | 1989-10-05 | 2001-01-22 | オプテイン，インコーポレイティド | 新規の遺伝子及びポリペチドの無細胞合成並びに単離 |
| US5747334A (en) | 1990-02-15 | 1998-05-05 | The University Of North Carolina At Chapel Hill | Random peptide library |
| US5726152A (en) * | 1990-09-21 | 1998-03-10 | Merck & Co., Inc. | Vascular endothelial cell growth factor II |
| US5716930A (en) * | 1991-04-10 | 1998-02-10 | Ludwig Institute For Cancer Research | Glial growth factors |
| US5530109A (en) * | 1991-04-10 | 1996-06-25 | Ludwig Institute For Cancer Research | DNA encoding glial mitogenic factors |
| US5834229A (en) | 1991-05-24 | 1998-11-10 | Genentech, Inc. | Nucleic acids vectors and host cells encoding and expressing heregulin 2-α |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5624902A (en) * | 1995-06-07 | 1997-04-29 | Torrey Pines Institute For Molecular Studies | Peptide inhibitors of calmodulin |
| US5912326A (en) | 1995-09-08 | 1999-06-15 | President And Fellows Of Harvard College | Cerebellum-derived growth factors |
| US5955594A (en) | 1997-04-30 | 1999-09-21 | Mishra; Lopa | Nucleic acids encoding proteins for early liver development |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| EP1073756A4 (en) | 1998-03-26 | 2003-01-22 | Gene Logic Inc | IDENTIFICATION OF A cDNA ASSOCIATED WITH ISCHEMIA IN HUMAN CARDIAC TISSUE |
| US6635249B1 (en) | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
| AU1086501A (en) | 1999-10-15 | 2001-04-30 | Carnegie Institution Of Washington | Rna interference pathway genes as tools for targeted genetic interference |
| US7375185B2 (en) | 2000-09-12 | 2008-05-20 | The United States Of America As Represented By The Department Of Health And Human Services | Cardiac myosin light chain kinase polypeptide, encoding nucleic acid, and methods of use |
| US6482624B2 (en) | 2000-11-14 | 2002-11-19 | Pe Corporation (Ny) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| AU2003240688A1 (en) * | 2002-05-24 | 2003-12-12 | Bayer Aktiengesellschaft | Regulation of human kinase |
| WO2004050894A2 (en) | 2002-11-27 | 2004-06-17 | Artesian Therapeutics, Inc. | Heart failure gene determination and therapeutic screening |
| CN1812776A (zh) | 2003-05-21 | 2006-08-02 | 得克萨斯州大学系统董事会 | 抑制蛋白激酶c－mu(pkd)用作心脏肥大和心力衰竭的疗法 |
| JP4792582B2 (ja) | 2003-08-21 | 2011-10-12 | 国立大学法人大阪大学 | 心肥大及びそれに起因する心疾患を予防または治療するための医薬組成物 |
| WO2005063983A1 (en) | 2003-12-29 | 2005-07-14 | Galapagos Genomics N.V. | Modulators of bone homeostasis identified in a high-throughput screen |
| US7341835B2 (en) | 2004-01-13 | 2008-03-11 | Affymetrix, Inc. | Methods of analysis of alternative splicing in mouse |
| WO2008128161A2 (en) | 2007-04-13 | 2008-10-23 | University Of Florida Research Foundation Inc. | Identification of cardiac specific myosin light chain kinase |
-
2007
- 2007-08-20 US US11/894,542 patent/US9580515B2/en active Active
- 2007-08-21 CA CA2661308A patent/CA2661308C/en not_active Expired - Fee Related
- 2007-08-21 WO PCT/CN2007/002531 patent/WO2008028405A1/en not_active Ceased
- 2007-08-21 ES ES13184566.1T patent/ES2625316T3/es active Active
- 2007-08-21 EP EP07800751A patent/EP2059594B1/en active Active
- 2007-08-21 EP EP17155285.4A patent/EP3202904A1/en not_active Withdrawn
- 2007-08-21 ES ES12154752.5T patent/ES2555543T3/es active Active
- 2007-08-21 EP EP13184566.1A patent/EP2730654B1/en active Active
- 2007-08-21 CN CN2007800300485A patent/CN101553568B/zh active Active
- 2007-08-21 CN CN201210072941.7A patent/CN102618562B/zh active Active
- 2007-08-21 EP EP12154752.5A patent/EP2484763B1/en active Active
- 2007-08-21 JP JP2009524883A patent/JP2010501167A/ja not_active Withdrawn
-
2014
- 2014-05-28 JP JP2014109644A patent/JP6339415B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-05 US US15/399,506 patent/US10227418B2/en active Active
- 2017-09-15 JP JP2017178155A patent/JP2018074996A/ja active Pending
-
2019
- 2019-02-08 US US16/271,716 patent/US20200207870A1/en not_active Abandoned
- 2019-08-15 JP JP2019149009A patent/JP2019213550A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US9580515B2 (en) | 2017-02-28 |
| EP2730654A3 (en) | 2014-07-02 |
| EP2484763B1 (en) | 2015-10-21 |
| EP2059594A4 (en) | 2009-12-09 |
| WO2008028405A1 (en) | 2008-03-13 |
| JP2010501167A (ja) | 2010-01-21 |
| EP3202904A1 (en) | 2017-08-09 |
| CN102618562A (zh) | 2012-08-01 |
| US20200207870A1 (en) | 2020-07-02 |
| CA2661308A1 (en) | 2008-03-13 |
| CN101553568B (zh) | 2012-06-27 |
| EP2730654A2 (en) | 2014-05-14 |
| JP6339415B2 (ja) | 2018-06-06 |
| EP2484763A3 (en) | 2012-11-07 |
| JP2018074996A (ja) | 2018-05-17 |
| EP2059594A1 (en) | 2009-05-20 |
| US20080260713A1 (en) | 2008-10-23 |
| EP2059594B1 (en) | 2012-10-17 |
| US10227418B2 (en) | 2019-03-12 |
| US20170313784A1 (en) | 2017-11-02 |
| CN102618562B (zh) | 2015-09-16 |
| CA2661308C (en) | 2020-07-21 |
| EP2730654B1 (en) | 2017-03-01 |
| JP2019213550A (ja) | 2019-12-19 |
| CN101553568A (zh) | 2009-10-07 |
| EP2484763A2 (en) | 2012-08-08 |
| JP2014221042A (ja) | 2014-11-27 |
| ES2555543T3 (es) | 2016-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2625316T3 (es) | Neuquinasa, una proteína corriente abajo de neuregulina | |
| US7291492B2 (en) | Histone deacetylase 9 | |
| AU773957B2 (en) | Protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction | |
| US20070117138A1 (en) | Splice variant cannabinoid receptor (cb1b) | |
| JP2006515159A (ja) | Ｍｋ２相互作用タンパク質 | |
| JPWO2000029571A1 (ja) | 新規膜貫通蛋白質をコードする遺伝子 | |
| ES2255152T3 (es) | Composiciones y metodo de proteinas de activacion sinaptica. | |
| ES2307767T3 (es) | Ensayos con el receptor epf, compuestos y composiciones terapeuticas. | |
| JP5335239B2 (ja) | ミオスタチンアイソフォーム | |
| ES2319386T3 (es) | Proteina 2 del canal del calcio de tipo trp (tlcc-2) humana. | |
| JP2000125888A (ja) | シアロアドヘシンファミリ―メンバ――３ | |
| JP4419077B2 (ja) | Ｃａｐ結合蛋白質 | |
| JPH11164692A (ja) | ヒトｒｃｅ１ | |
| ES2324779T3 (es) | Proteina que se une a akt2. | |
| CN102766202B (zh) | Phf14 c端蛋白、其多克隆抗体及应用 | |
| JP4016280B2 (ja) | 脂質代謝改善物質のスクリーニング方法 | |
| JP2003189883A (ja) | 新規ユビキチン特異プロテアーゼ | |
| BG63548B1 (bg) | Полипептиди, съдържащи протеинови домени на gax, включени в транскрипцията и/или взаимнодействащи сдруги протеини, съответни нуклеинови киселини и тяхното използване | |
| JPH11243972A (ja) | アミノペプチダーゼファミリーのメンバー、ｍｅｔｐｒｏ ０２ | |
| US20230181672A1 (en) | Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms | |
| JP2002238578A (ja) | ラットｅｄｇ７受容体 | |
| WO2001038531A1 (fr) | Nucleoproteine humaine possedant un domaine www et polynucleotide codant cette nucleoproteine | |
| Scott | Binding of Sry1, Sry2, and Sry3 to promoter regions of the Rattus norvegicus Ace and Ace2 genes | |
| US20060116338A1 (en) | Mammalian early developmental regulator gene | |
| WO2002055657A2 (en) | Protein-protein interactions |